Biotechnology drug pricing has become the most politically and commercially contested issue in healthcare policy. The Inflation Reduction Act's drug price negotiation provisions are directly targeting biotechnology's highest-revenue products. HTA bodies in Europe — NICE in the UK, G-BA in Germany, HAS in France — are applying increasingly rigorous cost-effectiveness standards to new biologic therapies. Gene therapy pricing — CASGEVY at $2.2-3.1 million, Hemgenix at $3.5 million — is testing the limits of healthcare budget tolerance. The development of outcome-based reimbursement models — paying for drugs based on clinical outcomes rather than fixed prices — is the primary policy response to the affordability challenge.
Topics Covered
• IRA Drug Price Negotiation
• European HTA Assessment
• Gene Therapy Pricing Models
• Outcome-Based Reimbursement
• Patient Access Programs
• Reference Pricing Dynamics
• Biosimilar Price Competition
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. IRA Drug Price Negotiation
4. European HTA Assessment
5. Gene Therapy Pricing Models
6. Outcome-Based Reimbursement
7. Patient Access Programs
8. Reference Pricing Dynamics
9. Biosimilar Price Competition
10. Competitive Landscape
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. IRA Drug Price Negotiation
Table 3. European HTA Assessment
Table 4. Gene Therapy Pricing Models
Table 5. Outcome-Based Reimbursement
Table 6. Patient Access Programs
Table 7. Reference Pricing Dynamics
Table 8. Biosimilar Price Competition
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Merck
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Express Scripts
CVS Caremark
OptumRx
Humana Pharmacy
